Novel research into cancers of the esophagus & stomach is being presented now at #GI26 during a rapid oral abstract session chaired by Dr. Matthew Strickland; Q&A to follow. #esosm #stcsm

meetings.asco.org/meetings/202...

A great opening session continues at #GI26 with “Oral Abstract Session A: Cancers of the Esophagus & Stomach” co-chaired by Dr. David Wang & Dr. Nathaniel Evans. #esocsm #stcsm
meetings.asco.org/meetings/202...

ATG-022 Earns Breakthrough Therapy Designation in China for Advanced Gastric/GEJ Adenocarcinoma The NMPA has granted breakthrough therapy designation to ATG-022 for previously treated gastric and gastroesophageal junction adenocarcinoma.

ATG-022 Earns Breakthrough Therapy Designation in China for Advanced Gastric/GEJ Adenocarcinoma
#GastricCancer #stcsm #GEJcancer
www.onclive.com/view/atg-022...

Program Guide – ASCO Meeting Program Guide

EFS in MATTERHORN: A Ph3 RCT of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin & docetaxel chemotherapy (FLOT) in resectable gastric/gastroesophageal junction cancer (GC/GEJC) - @YJanjigianMD et al. #ASCO25 LBA5 meetings.asco.org/abstracts-pr... #NCT04592913 #stcsm #esocsm

HLX22 Receives FDA Orphan Drug Designation in Gastric Cancer The FDA has granted orphan drug designation to HLX22 for the treatment of patients with gastric cancer based on positive data from the HLX22-GC-201 study.

HLX22 Receives FDA Orphan Drug Designation in Gastric Cancer
@fda.gov #FDA #stcsm
www.onclive.com/view/hlx22-r...

T-DXd Improves OS in Unresectable/Metastatic HER2+ Gastric/GEJ Adenocarcinoma T-DXd improved overall survival in unresectable/metastatic HER2-positive gastric/GEJ adenocarcinoma after a trastuzumab-containing regimen.

T-DXd Improves OS in Unresectable/Metastatic HER2+ Gastric/GEJ Adenocarcinoma
#stcsm #oncology #MedEd
www.onclive.com/view/t-dxd-i...

Study S2303

Study S2303 is for people who are seeking further treatment for advanced #stomach or #esophageal #cancer. It tests adding an #immunotherapy drug (#nivolumab) to usual treatment. SWOG.org/S2303. 1-800-4-CANCER. #esocsm #stcsm #gicsm #gastriccancer

So much excited data shared on Day 1️⃣ of #GI25 from #biomarker 🎯 testing in #esocsm #stcsm to the role of #RT in #esocsm in light 💡 of #ESOPEC. Excited for more great science and discovery on Day 2️⃣!

Tremelimumab and durvalumab as neoadjuvant or non-operative management strategy of patients with microsatellite instability-high resectable gastric or gastroesophageal junction adenocarcinoma: the INF... In resectable gastric/gastroesophageal junction adenocarcinoma, microsatellite instability-high (MSI-H) confers improved survival, but limited benefit…

Exciting #GIonc INFINITY ♾ #Ph2 trial

Neoadjuvant #IO in #stcsm #esocsm using #treme + #durva ~60% pCR

12m 🚫🔪#survival ~ 64%.

#Ph3 data needed, but organ preservation possible!

🔗: sciencedirect.com/science/arti...

Next-Generation Sequencing of Advanced GI Tumors Reveals Individual Treatment Options [Mar 30, 2020] Bitzer et al. @ASCO_pubs ow.ly/MuHP30qAEI0 #PrecisionMedicine #ancsm #crcsm #esocsm #hpbcsm #pancsm #sbcsm #stcsm n=96, Apr 2016 - Feb 2018

FDA approves nivolumab and hyaluronidase-nvhy for subcutaneous injecti FDA approves nivolumab and hyaluronidase-nvhy for subcutaneous injection

#OncSky #MedSky

Another subcutaneous #ImmunoOnc therapy (nivo) now officially in the toolkit 👇

#melsm #lcsm #kcsm #blcsm #gicsm #stcsm #esocsm

www.fda.gov/drugs/resour...

SWOG S2303 study

Do you have #esophageal or #stomach #cancer that has spread or can’t be removed with surgery? If initial treatment didn’t work or stopped working, study S2303 may be an option for you.
SWOG.org/S2303. 1-800-4-CANCER. #esocsm #stcsm #gicsm #PARAMUNE

Final overall survival results from KEYNOTE-811 in HER2+ metastatic gastric cancer - VJOncology Filippo Pietrantonio, MD, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, discusses the final overall survival (OS) analysis of the...

November is gastric cancer awareness month and we are sharing updates in the field ⭐

At #ESMO24, we spoke with Filippo Pietrantonio on the final OS results from KEYNOTE-811 in HER2+ metastatic gastric cancer.

👉See the video below! 👈

https://buff.ly/4ezvhmz

#stcsm #gism

Long-term survivorship concerns of patients with esophageal and gastric cancer - VJOncology Jessie Elliott, FRCS, PhD, Trinity St. James’s Cancer Institute, Dublin, Ireland, discusses the long-term survivorship concerns of patients with esophageal...

November is gastric cancer awareness month and we are sharing updates in the field ⭐

At #ESMO24, we spoke with Jessie Elliott on long-term survivorship concerns of patients with esophageal and gastric cancer.

👉See the video below! 👈

https://buff.ly/48WQh5R

#stcsm #gism